Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas B. Powles, Ignacio Durán, Michiel S. van der Heijden et al. · The Lancet · 2017
Cited by 1,408 works. doi:10.1016/s0140-6736(17)33297-x Open-access PDF
Authors
- Thomas B. Powles
- Ignacio Durán
- Michiel S. van der Heijden
- Yohann Loriot
- Nicholas J. Vogelzang
- Ugo De Giorgi
- Stéphane Marie. Oudard
- Margitta M. Retz
- Daniel Castellano
- Aristotelis Bamias
- Aude Fléchon
- Gwénaëlle Gravis
- Syed A. Hussain
- Toshimi Takano
- Ning Leng
- Edward Ernest Kadel
- Romain Banchereau
- Priti S. Hegde
- Sanjeev Mariathasan
- Na Cui
References
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer